BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: WHO declares Ebola outbreak a public health emergency of international concernBreaking News: WHO declares Ebola outbreak a public health emergency of international concern
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Degradation of motor neurons
Neurology/Psychiatric

A novel CAPN2-targeting ASO, AMX-0114, rescues neurite degeneration in vitro

March 24, 2023
Calcium-dependent protease calpain-2 (CAPN2) has been previously proposed as a critical effector of axonal degeneration, which is a key early...
Read More
Neurology/Psychiatric

Biohaven licenses ex-China rights to Highlightll’s TYK2/JAK1 inhibitor for neurological disorders

March 23, 2023
Biohaven Ltd. has acquired global rights, excluding China regions, from Hangzhou Highlightll Pharmaceutical Co. Ltd. for TLL-041, now designated BHV-8000, an oral, brain-penetrant, highly selective, dual TYK2/JAK1 inhibitor, for neurological disorders.
Read More
Illustration demonstrating muscle contraction in amyotrophic lateral sclerosis.
Neurology/Psychiatric

Cav2 calcium channel modifier GV-58 shows beneficial effects in experimental ALS

March 23, 2023
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by failure of motor neurons that lead to paralysis. To date, no treatment exists for ALS that focuses on improving neuromuscular transmission, which would improve quality of life for ALS patients.
Read More
Neurology/Psychiatric

Hangzhou Healzen Therapeutics presents new KCNQ2/3 potassium channel activators

March 21, 2023
Hangzhou Healzen Therapeutics Co. Ltd. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, among others.
Read More
Neurology/Psychiatric

Artivila Therapeutics describes new SARM1 inhibitors

March 21, 2023
Artivila Therapeutics (Shenzhen) Co. Ltd. has identified NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of Alzheimer's and Parkinson's diseases, multiple sclerosis, amyotrophic lateral sclerosis and peripheral neuropathy.
Read More
Spinal cord
Neurology/Psychiatric

Nurexone reports recovery of mice with spinal cord injuries after intranasal Exopten delivery

March 21, 2023
Nurexone Biologic Inc. has released further results from a preclinical study of Exopten demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.
Read More
Neural network
Neurology/Psychiatric

Small-molecule activators of KCC2 reduce neuronal excitability, show efficacy in benzodiazepine-resistant status epilepticus

March 20, 2023
The neuron-specific K+/Cl- co-transporter KCC2 is involved in the shift from depolarizing to hyperpolarizing γ-aminobutyric acid receptor (GABAAR) currents and subsequent synaptic inhibition.
Read More
DNA illustration
Biomarkers

Investigators identify novel variants in the KIAA1109 gene related to Alkuraya-Kucinskas syndrome

March 20, 2023
Investigators from the Thomas Jefferson University have presented a case report of a 27-year-old pregnant patient in whom cystic hygroma, extensive anasarca, bilateral pleural effusions, ascites, abnormally curved sacrum and hydrocephalus with parenchymal volume loss, among others were detected by prenatal imaging during pregnancy (onset was at about 21 weeks of gestation).
Read More
Brain and encephalography
Neurology/Psychiatric

BHV-7000 demonstrates efficacy and safety in maximal electroshock seizure rat model

March 20, 2023
Researchers from Biohaven Pharmaceutical Holding Co. Ltd. presented preclinical data for...
Read More
Brain and DNA
Neurology/Psychiatric

Quralis announces program targeting UNC13A mis-splicing for neurodegenerative diseases

March 20, 2023
Quralis Corp. has launched a program that targets UNC13A mis-splicing, a critical genetic alteration...
Read More
Previous 1 2 … 191 192 193 194 195 196 197 198 199 … 2803 2804 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing